AEROMICS
Aeromics is a clinical candidate targeting a molecular water channel for the treatment of cerebral edema in stroke. A paradigm shift in its understanding of water physiology was the discovery aquaporins, proteins that form water channels to allow water into and out of cells, by Peter Agre (2003 Nobel Prize in Chemistry). Despite the vital role of aquaporins in maintaining water homeostasis and its implications in various disease states, therapeutic agents targeting aquaporins have until now remained elusive. Aeromics’ drug candidate, AER-271, targets aquaporin-4 (AQP4), the primary water channel in the brain, and has best-in-class credentials for acute intravenous therapy for stroke-related cerebral edema (CE).
AEROMICS
Industry:
Biotechnology Life Science Therapeutics
Founded:
2006-01-01
Address:
Cleveland, Ohio, United States
Country:
United States
Website Url:
http://www.aeromics.com
Total Employee:
1+
Status:
Active
Contact:
216-772-1004
Email Addresses:
[email protected]
Total Funding:
12.61 M USD
Technology used in webpage:
Viewport Meta SSL By Default LetsEncrypt Content Delivery Network Euro Typekit Squarespace Squarespace Hosted 1and1 Email Solutions
Similar Organizations
Axcella
Axcella is a biotechnology company providing therapeutics development solutions.
Enliven Therapeutics
Enliven Therapeutics is a precision oncology company developing small molecule therapies to extend and improve patient lives.
Spero Therapeutics
Spero Therapeutics is developing first in class therapeutics for treatment of gram-negative infections.
Current Advisors List
Current Employees Featured
Founder
Investors List
Connecticut Innovations
Connecticut Innovations investment in Series A - Aeromics
Broadview Ventures
Broadview Ventures investment in Debt Financing - Aeromics
Official Site Inspections
http://www.aeromics.com
- Host name: 198.49.23.145
- IP address: 198.49.23.145
- Location: New York United States
- Latitude: 40.7157
- Longitude: -74
- Metro Code: 501
- Timezone: America/New_York
- Postal: 10013
